115 related articles for article (PubMed ID: 12895351)
1. [Detection of serum levels of MMP-9 and VEGF in patients with bladder cancer].
Guan KP; Hou SK; Yan Z; Ye HY
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):430-2. PubMed ID: 12895351
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
3. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
[TBL] [Abstract][Full Text] [Related]
4. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer.
Nakanishi R; Oka N; Nakatsuji H; Koizumi T; Sakaki M; Takahashi M; Fukumori T; Kanayama HO
Urol Int; 2009; 83(1):98-106. PubMed ID: 19641368
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.
Donmez G; Sullu Y; Baris S; Yildiz L; Aydin O; Karagoz F; Kandemir B
Pathol Res Pract; 2009; 205(12):854-7. PubMed ID: 19762163
[TBL] [Abstract][Full Text] [Related]
6. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
7. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer.
Bernardini S; Fauconnet S; Chabannes E; Henry PC; Adessi G; Bittard H
J Urol; 2001 Oct; 166(4):1275-9. PubMed ID: 11547057
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma.
Gao ZL; Zhang C; Du GY; Lu ZJ
Hepatogastroenterology; 2007; 54(77):1591-5. PubMed ID: 17708308
[TBL] [Abstract][Full Text] [Related]
10. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
11. [Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues].
Liu R; Pu DM; Cheng YX; Yin L
Zhonghua Yi Xue Za Zhi; 2007 May; 87(19):1326-9. PubMed ID: 17727777
[TBL] [Abstract][Full Text] [Related]
12. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
Zhao J; Liu XY; Zhang QY; Jiang W
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
[TBL] [Abstract][Full Text] [Related]
13. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
14. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
15. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
[TBL] [Abstract][Full Text] [Related]
16. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.
Chan LW; Moses MA; Goley E; Sproull M; Muanza T; Coleman CN; Figg WD; Albert PS; Ménard C; Camphausen K
J Clin Oncol; 2004 Feb; 22(3):499-506. PubMed ID: 14752073
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
Laack E; Scheffler A; Burkholder I; Boeters I; Andritzky B; Schuch G; Görn M; Vohwinkel G; Edler L; Fiedler W; Hossfeld DK
Lung Cancer; 2005 Oct; 50(1):51-8. PubMed ID: 15992959
[TBL] [Abstract][Full Text] [Related]
18. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
19. Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression.
Kim SH; Cho NH; Kim K; Lee JS; Koo BS; Kim JH; Chang JH; Choi EC
J Surg Oncol; 2006 Mar; 93(4):330-7. PubMed ID: 16496371
[TBL] [Abstract][Full Text] [Related]
20. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]